PetVivo Holdings, Inc. Encouraged Over Positive Response Received at 2023 American College of Veterinary Surgeons Conference
- PetVivo received positive response for Spryng™ at ACVS conference
- Two presentations highlighted the benefits of Spryng™ for joint-related afflictions
- Clinical study showed significant improvements in pain and quality of life scoring
- Spryng™ is a non-invasive alternative for patients with cranial cruciate disease
- None.
MINNEAPOLIS, MN, US, Oct. 25, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it received a very favorable response from veterinarians regarding the Company’s innovative product Spryng™, with OsteoCushion™ technology at the American College of Veterinary Surgeons (“ACVS”) conference held on October 11th to October 14th, 2023 in Louisville, Kentucky.
SPRYNG™ with OsteoCushion™ Technology is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; Spryng microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis.
Two presentations at the ACVS Conference heightened the enthusiastic interest in veterinarians to learn more about Spryng and consider its use in their practices. The first presentation was given to an overflowing hall of veterinarians by Jessica Rychel, DVM, DACVSMR and Lindsey M. Fry, DVM, DACVSMR, CVPP, CCRP, cVMA, DVM, DACVSMR, CCRP, CVPP, cVMA, both founders of Red Sage Integrative Veterinary Partners; this presentation was entitled “When Surgery is Not an Option- a Multimodal Approach to Management of Orthopedic Cases”. Joseph Manning, DVM, and Senior Technical Veterinarian for the Company, gave the second presentation related to the use of Spryng™ with OsteoCushion™ Technology entitled “Advancements in Intra-Articular Therapies: A Naturally Derived Option for Joints”.
Finally, the Company released the completed results of a clinical study conducted by Ethos Veterinary Health at the ACVS annual conference; the clinical study examined the benefit and tolerability of an intra-articular injection of a collagen-elastin biomaterial (i.e. Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture. Dr. Erik Kleeman, DVM presented the clinical study poster at the ACVS Conference. The clinical study results demonstrated that there were significant improvements in all of the primary and secondary clinical variables throughout the study period (pain, lameness, quality of life scoring). In summary, this study demonstrated that Spryng™ is a reasonable, non-invasive alternative for patients with cranial cruciate disease (“CCD”) when patient and/or owner factors preclude surgical intervention. To view the poster presentation and a video interview of Dr. Kleeman discussing the clinical study presented at the ACVS annual conference please visit the following:
“The ACVS Conference provided us an excellent forum to demonstrate to leading veterinary surgeons our innovative medical device, Spryng, with OsteoCushion Technology, for the management of osteoarthritis” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “The conference resulted in us achieving our main objective, which was to explain to veterinarians that Spryng could be considered for first-line therapy in any animal, including those animals not able or willing to take oral medications and those not able or willing to undergo surgery.”
For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit https://petvivo.com/ and https://sprynghealth.com/.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
The Company has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint-related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is Spryng™ with OsteoCushion™ technology?
What were the results of the clinical study?
Is Spryng™ a non-invasive alternative for patients with cranial cruciate disease?
